United Therapeutics: UBS Maintains Buy, Raises PT to $560 from $415.

United Therapeutics: UBS Maintains Buy, Raises PT to $560 from $415.

UBS Group has maintained its "Buy" rating on United Therapeutics Corp. (NASDAQ: UTHR) while raising its price target to $560 from $415. This move comes following the successful Phase 3 TETON-2 trial results, which demonstrated significant improvements in forced vital capacity compared to a placebo for idiopathic pulmonary fibrosis (IPF) patients [2].

The positive trial outcomes have led UBS to increase its risk-adjusted peak sales forecast for Tyvaso in IPF to $3.3 billion from $1.5 billion. The drug's potential to become a standard of care in the $4 billion global IPF market is cited as a key factor driving this forecast increase [2].

UBS has identified several upcoming catalysts for United Therapeutics, including the detailed TETON-2 results presentation at the ERS Congress on September 28 and the TETON-1 trial readout expected in the first half of 2026. Additionally, the company has expanded its partnership with MannKind Corporation to develop a second dry powder inhalation therapy, further bolstering its treatment offerings [2].

Other analysts have also responded positively to the trial results. Jefferies has raised its price target for United Therapeutics to $564, maintaining a "Buy" rating, while Cantor Fitzgerald continues to support the stock with an "Overweight" rating and a $405 price target [2].

United Therapeutics' strong financial health, with an "Excellent" InvestingPro overall score of 3.98, and impressive gross profit margins of 89% further underscore the company's potential [2].

References:
[1] https://www.marketbeat.com/instant-alerts/heico-nysehei-price-target-raised-to-37500-at-ubs-group-2025-08-27/
[2] https://www.investing.com/news/analyst-ratings/united-therapeutics-stock-price-target-raised-to-560-from-415-at-ubs-93CH-4223939